Drug Pricing Policies in the United States and Globally: From Development to Delivery
October 24, 2018, 8:00 AM – 4:30 PM
Harvard Law School
Keynote address
VIDEO: Welcome remarks, Daniel Aaron, I. Glenn Cohen, and Quentin Palfrey
VIDEO: Keynote Address, Ronald Piervincenzi
VIDEO: Keynote Address, Joe Grogan Lunchtime
Slide Presentations
- Jami Taylor: “Best Practices in Drug Pricing”
- Peter B. Bach: “Cancer Drug Pricing & The Last Mile of Innovation”
- Sean Dickson: “Market Incentives and Market Power”
- Lauren Galinsky: “Access to Medicines in Global Health”
- Sara Gerke: “AI in Drug Discovery and Clinical Trials”
- Joe Grogan: “Keynote Address”
- Hannah Kettler: “From Development to Delivery Globally: Case of Vaccines”
- Ron Piervincenzi: “USP Standards: Facilitating a fair and competitive marketplace and advancing public health”
- Surya Singh: “From Development to Delivery in the US”
- Muhammad Zaman: “Access, Quality, and Pricing: Low and Middle Income Countries”
Panel videos
Panel I: From Development to Delivery in the United States
VIDEO: Panel 1, Sean Dickson, “From Development to Delivery in the United States”
VIDEO: Panel 1, Surya Singh, From Development to Delivery in the United States”
VIDEO: Panel 1, Michael Caljouw, “From Development to Delivery in the United States”
VIDEO: Panel 1, Audience Q & A, “From Development to Delivery in the United States”
Moderator: Carmel Shachar, Executive Director, Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics and Lecturer at Law, Harvard Law School
Panel II: From Development to Delivery Globally
VIDEO: Panel 2, Amy Flood, “From Development to Delivery Globally”
VIDEO: Panel 2, Lauren Galinsky, “From Development to Delivery Globally”
VIDEO: Panel 2, Hannah Kettler, “From Development to Delivery Globally”
VIDEO: Panel 2, Audience Q & A, “From Development to Delivery Globally”
Moderator: Quentin Palfrey, co-Director, Global Access in Action, Berkman Klein Center for Internet and Society at Harvard University
Panel III: Best Practices in Pricing Policy for Essential Drugs
VIDEO: Panel 3, Peter B. Bach, “Best Practices in Pricing Policy for Essential Drugs”
VIDEO: Panel 3, Annette Gaudino, “Best Practices in Pricing Policy for Essential Drugs”
VIDEO: Panel 3, Jami Taylor, “Best Practices in Pricing Policy for Essential Drugs”
VIDEO: Panel 3, Audience Q & A, “Best Practices in Pricing Policy for Essential Drugs”
Moderator: William W. Fisher, WilmerHale Professor of Intellectual Property Law, Harvard Law School, and Faculty Director, Berkman Klein Center for Internet and Society at Harvard University
Panel IV: Innovations in Drug Discovery and Policy: From Bitter Pills to Artificial Intelligence
VIDEO VIDEO: Panel 4, Muhammad Zaman, “Innovations in Drug Discovery and Policy
VIDEO: Panel 4, Sara Gerke, “Innovations in Drug Discovery and Policy”
VIDEO: Panel 4, Audience Q & A, “Innovations in Drug Discovery and Policy
Moderator: Ashveena Gajeelee, Global Access in Action and Fellow at Berkman Klein Center for Internet and Society
Agenda
8:00 – 8:30am, Registration
8:30 – 8:45am, Welcome Remarks
- I. Glenn Cohen, James A. Attwood and Leslie Williams Professor of Law and Faculty Director, Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard Law School
- Quentin Palfrey, co-Director, Global Access in Action, Berkman Klein Center for Internet and Society at Harvard University
8:45 – 9:30am, Keynote Address
- Ronald Piervincenzi, CEO, United States Pharmacopeial Convention
9:30 – 10:45am, Panel I: From Development to Delivery in the United States
- Peter B. Bach, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- Surya Singh, Vice President and Chief Medical Officer, Specialty Pharmacy, CVS Health
- Michael Caljouw, Vice President, State Government and Regulatory Affairs, Blue Cross Blue Shield of Massachusetts
- Moderator: Carmel Shachar, Executive Director, Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics and Lecturer at Law, Harvard Law School
10:45 – 11:00am, Break
11:00 am – 12:15 pm, Panel II: From Development to Delivery Globally
- Amy Flood, Senior Vice President, Public Affairs, Gilead Sciences, Inc.
- Lauren Galinsky, PIH’s Senior Clinical Operations Advisor, Partners in Health
- Hannah Kettler, Senior Program Officer on the Life Sciences Partnerships team at the Bill and Melinda Gates Foundation
- Moderator: Quentin Palfrey, co-Director, Global Access in Action, Berkman Klein Center for Internet and Society at Harvard University
12:15 – 12:45pm, Keynote Address
- Joe Grogan, Associate Director, Health Programs, Office of Management and Budget
12:45 – 1:45pm, Networking Lunch
1:45 – 3:00pm, Panel III: Best Practices in Pricing Policy for Essential Drugs
- Peter B. Bach, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- Annette Gaudino, HIV/HCV Project Co-Director, Treatment Action Group (TAG)
- Aaron S. Kesselheim, Director, Program on Regulation, Therapeutics, and Law (PORTAL), Brigham & Women’s Hospital, and Associate Professor of Medicine, Harvard Medical School
- Jami Taylor, Managing Director, Stanton Park Capital
- Moderator: William W. Fisher, WilmerHale Professor of Intellectual Property Law, Harvard Law School, and Faculty Director, Berkman Klein Center for Internet and Society at Harvard University
3:00 – 3:15pm, Break
3:15 – 4.30 pm, Panel IV: Innovations in Drug Discovery and Policy: From Bitter Pills to Artificial Intelligence
- Sara Gerke, Research Fellow in Precision Medicine, Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard Law School
- Muhammad Zaman, Howard Hughes Medical Institute Professor of Biomedical Engineering and International Health at Boston University
- Moderator: Ashveena Gajeelee, Research Fellow, Global Access in Action, Berkman Klein Center for Internet and Society at Harvard University
Sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, Global Access in Action at the Berkman Klein Center for Internet and Society at Harvard University, and the Harvard Health Law Society, with support from Gilead Sciences, Inc.